Analysis of Clinical Efficacy of Bevacizumab Combined with SOX Chemotherapy in the Treatment of Patients with Stage III to IV Gastric Cancer

Abstract

Objective . To investigate the clinical efficacy of bevacizumab combined with tigeo combined with oxaliplatin (SOX regimen) in the treatment of stage Ⅲ ～ Ⅳ gastric cancer, and to analyze the effects on serum tumor markers and quality of life. Methods. A total of 44 patients with stage Ⅲ ～ Ⅳ gastric cancer admitted to our hospital from January 2018 to December 2018 were selected and divided into control group and observation group with 22 cases in each according to different treatment regimens. Control group adopts the SOX chemotherapy treatment, observation group in the control group given on the basis of bevacizumab treatment compared two groups of curative effect, observe two groups before and after treatment serum tumor markers: sugar chain antigen (CA19-9, CA242), carcinoembryonic antigen (CEA), as well as the core of quality of life scale (QLQ-C30) score results observation group treatment the total effective rate was 77.27%, 40.91% higher than that of control group, the difference was statistically significant (P ＜ 0.05); After treatment, the levels of serum CEA CA19-9 CA242 in the observation group were lower than those in the control group, and the differences were statistically significant (P ＜ 0.05). After treatment, QLQ-C30 scores in both groups were higher than before treatment, and observation group was higher than control group, the difference was statistically significant (P ＜ 0.05). Conclusion Bevacizumab combined with SOX has a significant effect on patients with stage Ⅲ ～ Ⅳ gastric cancer, which can reduce the level of serum tumor markers and improve the quality of life.